Forest Expects Memantine NDA In June; Readies For Benicar Sampling
Executive Summary
Forest expects to submit an NDA for the Alzheimer's drug memantine in June, the company told analysts at the Deutsche Bank healthcare conference in Baltimore May 7
You may also be interested in...
Forest Adding 600 Sales Reps For Memantine, Lercanidipine Launches
Forest is planning to add a 600-rep sales force to support the upcoming launches of the Alzheimer's agent memantineand the anti-hypertensive lercanidipine, President Kenneth Goodman told analysts Oct. 15
Forest Adding 600 Sales Reps For Memantine, Lercanidipine Launches
Forest is planning to add a 600-rep sales force to support the upcoming launches of the Alzheimer's agent memantineand the anti-hypertensive lercanidipine, President Kenneth Goodman told analysts Oct. 15
Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor
Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force